Molecular Partners AG
NASDAQ:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Molecular Partners AG
NASDAQ:MOLN
|
CH |
|
E
|
Euronet Worldwide Inc
XMUN:EEF
|
US |
|
S
|
Standard Chartered PLC
XMUN:STD
|
UK |
|
Standard Chartered PLC
F:STD0
|
UK |
|
I
|
InTiCa Systems SE
XMUN:IS7
|
DE |
|
S
|
Standard Chartered PLC
SWB:STD
|
UK |
|
S
|
Standard Chartered PLC
DUS:STD
|
UK |
|
A
|
Alzchem Group AG
DUS:ACT
|
DE |
Intrinsic Value
Is MOLN undervalued or overvalued?
See the intrinsic value estimate for 
Molecular Partners AG and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
MOLN looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with MOLN’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Molecular Partners Does
Molecular Partners is a Swiss biotechnology company that develops DARPin drugs, which are lab-made protein binders designed to attach tightly to disease targets. Its work centers on turning these engineered molecules into medicines for cancer and other serious diseases, with a heavy focus on treatments that can be given as targeted therapies rather than broad chemical drugs.
- Headquarters
- Switzerland CH
- Employees
- 134
- IPO date
- Oct 22, 2014
Revenue & Expenses Breakdown
Molecular Partners AG
Earnings Waterfall
Molecular Partners AG
The intrinsic value for Molecular Partners AG (MOLN) under the Base Case is hidden USD.
Compared with the current market price of 3.75 USD, the stock appears hidden.